Inflammatory bowel disease surgery in the biologic therapy era

Scott A. Strong*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations

Abstract

Purpose of review: The relationship between surgery and biologic agents in the management of patients with inflammatory bowel disease continues to be a source of interest for both surgeons and clinicians. Recent findings: The role of biologic agents in patients with varying presentations of Crohn's disease or ulcerative colitis continues to evolve. However, the currently available biologic therapies are clearly not the panacea we have desired because they have only marginally decreased the frequency with which operative intervention is required and may have increased the risk for infectious postoperative complications in the nonelective setting. Compared to surgery, biologic agents are also significantly more costly and may not provide any greater gain in quality of life. SUMMARY: Future studies must focus on the use of surgery and emerging biologic agents as complementary therapies designed to safely control inflammatory disease while providing objective value.

Original languageEnglish (US)
Pages (from-to)349-353
Number of pages5
JournalCurrent Opinion in Gastroenterology
Volume28
Issue number4
DOIs
StatePublished - Jul 1 2012

Keywords

  • biologic agents
  • cost
  • inflammatory bowel disease
  • operative complications
  • surgery

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'Inflammatory bowel disease surgery in the biologic therapy era'. Together they form a unique fingerprint.

Cite this